Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. is a technology-driven genetic testing company focused on providing comprehensive and flexible diagnostic solutions. Its services include next-generation sequencing (NGS) for oncology, infectious disease, and reproductive health. By combining lab expertise with software engineering, Fulgent offers scalable genetic testing that supports personalized medicine, public health screening, and precision oncology diagnostics across the healthcare spectrum.
The company’s growth is supported by its broad testing portfolio, proprietary technology platform, and expansion into oncology and hereditary cancer screening. During the pandemic, Fulgent gained visibility through high-volume COVID-19 testing, which helped scale infrastructure and brand recognition. Now, its strategic pivot into high-growth segments like pharmacogenomics and liquid biopsy testing aims to fuel long-term demand from healthcare systems and biopharma partners.
Fulgent continues to reinvest in innovation, building partnerships and expanding its lab capabilities to enhance service offerings. With increasing demand for early disease detection, population health tools, and personalized treatment plans, the company is well positioned to drive adoption of advanced diagnostics. Its cost-effective, tech-enabled model supports ongoing evolution in clinical genomics and public health. Chart
Follow Trade Ideas on 